Gemtuzumab in Treating Patients With Myelodysplastic Syndrome (NCT00022321)
Monoclonal antibodies, such as the antibody-drug conjugate or ADC gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
This is a randomized phase II trial to study the effectiveness of gemtuzumab in treating patients who have myelodysplastic syndrome.
This trial is sponsored by UCLA Jonsson Comprehensive Cancer Center. 
- Condition: Myelodysplastic Syndromes
- Phase: II
- Estimated Enrollment:
- Start: September 2001
- Last verified: June 2002
Last Editorial review: July 23, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.